UNSPSC 51132201: Acetaminophen/caffeine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132201 Acetaminophen/caffeine is a Commodity code that does not align with the recent state and local opportunities tagged under it. The code's nominal scope—a single combination analgesic product—does not match the procurement activity actually occurring: the three most recent opportunities solicited naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription fulfillment programs (Texas Health and Human Services Commission), and multi-source generic pharmaceuticals and OTC products across a multistate cooperative (Minnesota MMCAP). These acquisitions span emergency response supplies, pharmacy benefit program redesign, and broad-based pharmaceutical distribution—scopes far wider than a single branded or generic medication pairing.

The geographic spread includes Florida, Texas, and Minnesota, representing distinct procurement models: a county health department buying emergency supplies through IFB, a state health agency conducting exploratory RFI for pharmacy program restructuring, and a multistate cooperative purchasing vehicle issuing RFP for pharmaceutical manufacturers. The mismatch between the code's narrow product definition and the heterogeneous, higher-level pharmaceutical and supply-chain procurement actually occurring suggests either mistagging in the source data or that this code captures minimal relevant activity in state and local markets. Business development professionals should verify code classification with issuing bodies before committing resources, as the nominal scope does not predict what will actually be solicited.